Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
LEVEL A (second line): after confirmed progression on standard first line treatment with dacarbazine.~LEVEL B (first line): when objective clinical response is observed in LEVEL A, patients will be included for first line treatment with bevacizumab~Inclusion Criteria:~* Histologically confirmed metastatic (unresectable) melanoma and with progressive disease~* WHO performance status 0-2~* Age \>18 years~* Able to undergo outpatient treatment~* Patients must have clinically and/or radiographically documented measurable disease according to RECIST criteria~* At least 4 weeks since adjuvant interferon alpha~* Recovered from prior chemotherapy~* Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start. Biopsy or fine needle aspiration within 5 days prior to study treatment start. Central venous line placement must be inserted at least 5 days prior to treatment start.~* Minimum required laboratory data:~Hematology: absolute granulocytes \> 1.0 x 109/L platelets \> 100 x 109/L Biochemistry: bilirubin \< 1.5 x upper normal limit serum creatinine within normal limits INR \< 1.5~* Before patient registration/randomization, written informed consent must be given according to national and local regulations.~Exclusion Criteria:~* No pregnant or lactating patients can be included~* No prior interferon alpha or IL-2 for metastatic disease~* No more than 1 prior chemotherapy regimen for metastatic disease~* No clinical evidence of coagulopathy~* No brain metastases~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~* No history of thrombosis~* No full-dose oral coumarin-derived anticoagulants (INR\>1.5) or heparin, thrombolytic agents, or chronic, daily treatment with aspirin (\>325 mg/day)~* No non-steroidal anti-inflammatory medications (those known to inhibit platelet function at doses used to treat chronic inflammatory diseases)~* No uncontrolled hypertension~* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).